FDA Releases Rules for Biosimilar Product Promotion Guidance
Published Date: 12/10/2025
Notice
Summary
The FDA just released clear rules for companies on how to advertise and label prescription biological drugs, including biosimilars and interchangeable biosimilars. This helps drug makers know what’s allowed when promoting these products, making sure info is honest and easy to understand. The new guidance is official as of December 10, 2025, so affected companies should update their ads soon to avoid any hiccups.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
New FDA Ad Rules for Biologics
On December 10, 2025, FDA issued final guidance on promotional labeling and advertising for prescription reference biological products, biosimilar products, and interchangeable biosimilar products. The guidance tells firms how to identify products, present study information, present data not in FDA-approved labeling (when consistent with labeling), compare biosimilars and reference products, and submit promotional communications to FDA; the recommendations apply regardless of medium (paper or digital).
Pharmacy Substitution Clarified
The guidance reiterates that an interchangeable biosimilar product may be substituted for the reference product without the prescribing healthcare provider's intervention (section 351(i)(3) of the Public Health Service Act). Decisions about pharmacy-level substitution remain subject to State pharmacy law.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-22426 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 9, 2026, to make sure the process is clear, useful, and not too much work. This helps CMS do its job better without wasting anyone’s time or money.
Next: 2025-22428 — Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended
Starting December 10, 2025, the Department of Homeland Security is speeding up the building of barriers and roads along the Texas border by temporarily skipping some usual rules and laws. This move helps stop illegal crossings and keeps the country safer, focusing on quick action without delays. It affects border communities and aims to boost security without mentioning extra costs or funding changes.